Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031, and BRL-32872 on protein kinase A-activated chloride current in guinea pig ventricular myocytes

Journal of Cardiovascular Pharmacology
J F FaivreA Bril

Abstract

The modulation of the protein kinase A-activated chloride current (PKA-I[Cl]) may lead to modification of the cardiac action potential shape. The purpose of this study was to evaluate the effects of glibenclamide, tedisamil, dofetilide, E-4031, and BRL-32872 on the PKA-I(Cl). Experiments were conducted by using the patch-clamp technique in guinea pig ventricular myocytes. PKA-I(Cl) was activated by application of 1 microM isoproterenol and was inhibited by 1 microM propranolol, 10 microM acetylcholine, or 1 mM 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid (SITS). The sulfonylurea receptor inhibitor, glibenclamide, inhibited PKA-I(Cl) at micromolar concentration. Among class III antiarrhythmic agents, tedisamil induced a dose-dependent inhibition of PKA-I(Cl) with a half effective concentration (EC50) of 7.15 microM (Hill coefficient, 0.54). This effect may contribute to action potential widening induced by tedisamil. In contrast, the selective inhibitors of the rapid component of the delayed rectifier K current (I[Kr]), dofetilide, and E-4031, as well as BRL-32872, that blocks I(Kr) and the L-type calcium current, did not significantly affect the amplitude of PKA-I(Cl), even at high concentrations (10-30 microM). T...Continue Reading

References

Aug 1, 1992·Circulation·K VaskaH S Klopfenstein
Jan 1, 1991·British Journal of Pharmacology·G N BeatchM J Walker
May 26, 1989·Science·R D Harvey, J R Hume
Aug 1, 1981·Pflügers Archiv : European journal of physiology·O P HamillF J Sigworth
Oct 1, 1982·Pflügers Archiv : European journal of physiology·G Isenberg, U Klockner
Sep 8, 1995·Cell·C F Higgins
Feb 1, 1993·Pflügers Archiv : European journal of physiology·R D Harvey
Jun 25, 1996·Proceedings of the National Academy of Sciences of the United States of America·P HartJ R Hume
Feb 1, 1996·Journal of Molecular and Cellular Cardiology·E Ruiz PetrichO F Schanne
Oct 4, 1996·The Journal of Biological Chemistry·S IsomotoY Kurachi
Oct 1, 1996·Journal of Cardiovascular Pharmacology and Therapeutics·P D WestT J Campbell

❮ Previous
Next ❯

Citations

Jun 21, 2006·Herzschrittmachertherapie & Elektrophysiologie·U RavensD Dobrev
May 3, 2002·Biochimica Et Biophysica Acta·Gilad Rimon, Mazal Rubin
Mar 27, 2001·British Journal of Pharmacology·T D BarrettB R Lucchesi
Feb 28, 2003·Expert Opinion on Investigational Drugs·Jan Nemec, Win-Kuang Shen
Dec 16, 2000·Expert Opinion on Investigational Drugs·S A Doggrell
Mar 5, 2004·Expert Opinion on Investigational Drugs·Bethan Freestone, Gregory Y H Lip
Aug 19, 2003·British Journal of Pharmacology·Guilda SarrafMichael J A Walker
Nov 8, 2005·Progress in Cardiovascular Diseases·Robert N Goldstein, Bruce S Stambler
May 15, 2003·Journal of Cardiovascular Pharmacology and Therapeutics·Paul Dorian
Aug 13, 1999·Journal of Cardiovascular Pharmacology·P S FischbachB R Lucchesi
Jan 5, 2000·Physiological Reviews·J R HumeB Horowitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.